AKASA has raised $60.0M in total across 1 funding round.
AKASA's investors include 20VC, 305 Ventures, 75 & Sunny, Addition, Altimeter Capital, Bond, Buckley Ventures, Scott Hartley, General Catalyst, Kearny Jackson, Lux Capital, Playground Global.
AKASA is a technology company that builds a generative AI platform for healthcare revenue cycle management (RCM), automating processes like prior authorizations, medical coding, claims management, and denial prevention.[1][2][5] It serves U.S. health systems and hospitals, solving high administrative costs and inefficiencies in RCM—such as labor-intensive tasks that burden providers with unnecessary expenses—by boosting accuracy, reducing denials, and improving revenue collection.[1][2][5] With customers representing over $120 billion in net patient revenue (about 10% of U.S. health system spending), AKASA has seen 10x growth in GenAI bookings, partnerships like Cerner (yielding 1%+ gross revenue gains on $3B), and its largest deal to date, fueling rapid expansion.[1][3]
Founded in 2018 as Alpha Health (later rebranded AKASA), the company emerged from four founders—Malinka Walaliyadde (CEO), Varun Ganapathi (CTO), Andy Atwal, and Ben Beadle-Ryby—who united Silicon Valley engineers with healthcare and RCM experts to tackle U.S. healthcare's administrative burdens on patients, providers, payers, and pharma (the "four Ps").[1][2][4][7] The idea stemmed from recognizing RCM's financial pain points amid high costs, leveraging early AI/ML before the GenAI boom; they capitalized on existing customers, talent, and funding when LLMs arrived two years ago to accelerate product launches.[2][6] Early traction included a $60M funding round and scaling automation via partnerships, evolving into a "Unified Automation" leader with a remote-friendly culture.[1][2][3]
AKASA rides the GenAI wave in healthcare, transforming RCM—a $1T+ U.S. market plagued by admin costs (15-20% of spending)—at a time when LLMs enable unprecedented automation amid staffing shortages, payer complexity, and post-pandemic pressures.[2][3][5][6] Timing is ideal: pre-GenAI foundations positioned them to launch faster than newcomers, capitalizing on hype while delivering real ROI (e.g., 10x bookings).[3][6] Market tailwinds include AI adoption for diagnostics/surgeries, regulatory pushes for efficiency, and investor focus on healthtech (e.g., portfolio peers like Ro, Virta).[7] They influence the ecosystem by publishing benchmarks, partnering with EHR giants like Cerner, and enabling providers to prioritize patients, potentially redefining RCM as AI-native.[1][2]
AKASA is primed for explosive growth, expanding its $120B+ revenue footprint with GenAI suite enhancements amid surging demand for RCM automation.[3] Trends like advanced LLMs, payer reforms, and value-based care will amplify their edge, potentially capturing more market share through acquisitions or global reach. Their influence may evolve from RCM specialist to full healthcare AI orchestrator, uniting fragmented systems—echoing their "fifth element" ethos to finally ease America's admin burden and refocus on patient care.[2][6]
AKASA has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $60.0M Series B | 20VC, 305 Ventures, 75 & Sunny, Addition, Altimeter Capital, Bond, Buckley Ventures, Scott Hartley, General Catalyst, Kearny Jackson, Lux Capital, Playground Global, Portal Ventures, Quona Capital, Rebel Fund, Smash Capital, Social Capital, SQN Venture Partners, ThirdLove, Tiger Global Management, Todd and Rahul's Angel Fund, Tribe Capital, Y Combinator, Allison Barr Allen, Jared Leto, Justin Mateen, Louis Beryl, Manik Gupta, Mark Cuban, Rashaun Williams, Scott Belsky, William Hockey, Zander Lurie |
